JEADV:4种炎症性皮肤病的应激反应:7273例成人痤疮、特应性皮炎、银屑病或化脓性汗腺炎患者的资料分析

2022-03-08 医路坦克 MedSci原创

成人痤疮,特应性皮炎,银屑病和化脓性汗腺炎是常见的慢性炎症性皮肤病,本文使用数字问卷评估了患有AA、AD、P或HS的成年人的感知压力,以及大量人群中自我感知的疾病严重程度和生活质量(QoL)。

    成人痤疮(AA),特应性皮炎(AD),银屑病(P)和化脓性汗腺炎(HS)是常见的慢性炎症性皮肤病,其发病率估计约为成年人口的15%。

这项由法国五个患者协会在2020年10月至2021年2月期间进行的观察性、横断面、非对比研究,使用数字问卷评估了患有AA、AD、P或HS的成年人的感知压力,以及大量人群中自我感知的疾病严重程度和生活质量(QoL)。

调查问卷确保了目标皮肤病之前已经过卫生保健专业人员的确认。压力使用有效的感知压力量表(PSS)进行评估,生活质量使用DLQI。 PSS问卷测量一个人的生活中的情况被认为是压力的程度。个人在PSS上的得分从0到40不等,得分越高表明感受到的压力越大。分数范围从0-13表示低感知压力,分数从14到26表示中等感知压力,分数从27到40表示高感知压力。DLQI评分高于10表示对患者生活质量的重要或非常重要的影响。此外,要求患者在进行研究时评估其皮肤病的严重程度(轻度,中度或重度),并确认是否为他们的皮肤病提供了心理支持。

总体而言,有7273名受试者参加了这项调查;1605名受试者患有AA,2538 AD,2329 P和801 HS。平均年龄为40.6岁;69.25%是女性,54.37%是就业。自我评估的疾病严重程度在49.73%的受试者中是中等的。

总共有66.3%的受试者报告压力得分高于27。AA,AD和P的结果显示,病情越严重,感知压力评分越高。HS患者无法观察到这一点。

虽然所有人群的压力水平都很高,特别是那些患有严重疾病的患者,但只有不到15%的患者得到了心理支持,当提出这种援助时,只有两名患者接受了这种援助。这一发现需要对未来以患者为中心的护理措施给予特别关注。

DLQI评分显着高于AA,AD和P患者的生活质量,特别是当压力评分高于27分时,应鼓励医疗保健专业人员开发不同的,以患者为中心的治疗方法;这些结果与观察到的压力的结果平行。

我们的研究表明,在慢性炎症性皮肤病患者中,心理压力是一个重要的问题,需要特别关注和个性化的心理支持。在慢性炎症性皮肤病中实施以患者为中心的管理可能会减少心理压力,潜在地改善治疗依从性和改善治疗结果。

文献来源:Misery L,  Chesnais M,  Merhand S, Perceived stress in four inflammatory skin diseases: an analysis of data taken from 7273 adult subjects with acne, atopic dermatitis, psoriasis or hidradenitis suppurativa.J Eur Acad Dermatol Venereol 2022 Feb 19

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]
    2022-03-08 ms7000002063403376

    学习了!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]
    2022-03-08 ms8000001465072660

    学习学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1826159, encodeId=56e518261599b, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon May 16 11:19:47 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784950, encodeId=553f1e8495083, content=<a href='/topic/show?id=f94e64211a' target=_blank style='color:#2F92EE;'>#EADV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6421, encryptionId=f94e64211a, topicName=EADV)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Fri Jun 03 14:19:47 CST 2022, time=2022-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748186, encodeId=1d701e48186cf, content=<a href='/topic/show?id=129533595e9' target=_blank style='color:#2F92EE;'>#化脓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33595, encryptionId=129533595e9, topicName=化脓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=443536086917, createdName=hb2020ye, createdTime=Mon Sep 05 11:19:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653860, encodeId=f0b61653860ce, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Fri Jul 08 02:19:47 CST 2022, time=2022-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200455, encodeId=e1c3120045581, content=学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d53e5423852, createdName=ms7000002063403376, createdTime=Tue Mar 08 08:33:42 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200450, encodeId=aadd1200450af, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bcbc6454654, createdName=ms8000001465072660, createdTime=Tue Mar 08 08:20:17 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445374, encodeId=f9bd14453e4b8, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547527, encodeId=a90b154e52724, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Mon Mar 07 11:19:47 CST 2022, time=2022-03-07, status=1, ipAttribution=)]

相关资讯

JAMA Dermatol:Secukinumab治疗与银屑病患者皮肌炎恶化的关系

Suckinumab是一种针对并中和白细胞介素(IL)17A的人类单克隆抗体。使用seckinumab治疗与免疫相关的不良反应。本文报告了首例银屑病患者的抗IL-17A相关皮肌炎(DM)加重病例。

JEADV:成年银屑病患者睡眠障碍的患病率及相关因素

银屑病患者睡眠障碍的研究始于80年代末,主要目的是调查生活质量和疾病负担,本文的目的是调查银屑病患者的睡眠特征,找出与睡眠障碍相关的临床、人口学和心理因素。

JEADV:Risankizumab长期治疗银屑病面积和严重程度指数以及相关的生活质量改善研究

银屑病是一种慢性、免疫介导的全身性炎症性疾病,本文研究了risankizumab治疗的中度至重度斑块状银屑病患者与ustekinumab相比,绝对PASI阈值的实现和健康相关生活质量指标的差异。

JAMA Dermatol:短期暴露于环境空气污染与银屑病病情的关系

银屑病是一种慢性炎症性疾病,具有反复发作的病程,环境因素,如感染和/或药物,可能会引发银屑病症状。空气污染是否会引发银屑病症状尚不清楚。这项研究的目的是调查短期暴露于环境空气污染是否与银屑病症状有关。

JEADV:富马酸二甲酯与传统银屑病治疗相比的疗效和安全性

富马酸衍生物(FAD),包括富马酸二甲酯(DMF),被批准用于成人患者中重度斑块状银屑病的全身治疗。本研究评估了DMF与其他全身治疗相比的长期疗效和安全性。

JAMA Dermatol:银屑病组织病理学诊断的视觉线索

炎症性皮肤病的临床和组织病理学诊断可能具有挑战性。我们将这两个组织学标准的总和称为ñsign。本文描述了ñsign在临床实践中作为银屑病诊断的视觉线索的潜在用途。